Cargando…
Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Centers for Disease Control and Prevention
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310634/ https://www.ncbi.nlm.nih.gov/pubmed/35862287 http://dx.doi.org/10.15585/mmwr.mm7129e1 |
| _version_ | 1784753429687566336 |
|---|---|
| author | Link-Gelles, Ruth Levy, Matthew E. Gaglani, Manjusha Irving, Stephanie A. Stockwell, Melissa Dascomb, Kristin DeSilva, Malini B. Reese, Sarah E. Liao, I-Chia Ong, Toan C. Grannis, Shaun J. McEvoy, Charlene Patel, Palak Klein, Nicola P. Hartmann, Emily Stenehjem, Edward Natarajan, Karthik Naleway, Allison L. Murthy, Kempapura Rao, Suchitra Dixon, Brian E. Kharbanda, Anupam B. Akinseye, Akintunde Dickerson, Monica Lewis, Ned Grisel, Nancy Han, Jungmi Barron, Michelle A. Fadel, William F. Dunne, Margaret M. Goddard, Kristin Arndorfer, Julie Konatham, Deepika Valvi, Nimish R. Currey, J. C. Fireman, Bruce Raiyani, Chandni Zerbo, Ousseny Sloan-Aagard, Chantel Ball, Sarah W. Thompson, Mark G. Tenforde, Mark W. |
| author_facet | Link-Gelles, Ruth Levy, Matthew E. Gaglani, Manjusha Irving, Stephanie A. Stockwell, Melissa Dascomb, Kristin DeSilva, Malini B. Reese, Sarah E. Liao, I-Chia Ong, Toan C. Grannis, Shaun J. McEvoy, Charlene Patel, Palak Klein, Nicola P. Hartmann, Emily Stenehjem, Edward Natarajan, Karthik Naleway, Allison L. Murthy, Kempapura Rao, Suchitra Dixon, Brian E. Kharbanda, Anupam B. Akinseye, Akintunde Dickerson, Monica Lewis, Ned Grisel, Nancy Han, Jungmi Barron, Michelle A. Fadel, William F. Dunne, Margaret M. Goddard, Kristin Arndorfer, Julie Konatham, Deepika Valvi, Nimish R. Currey, J. C. Fireman, Bruce Raiyani, Chandni Zerbo, Ousseny Sloan-Aagard, Chantel Ball, Sarah W. Thompson, Mark G. Tenforde, Mark W. |
| author_sort | Link-Gelles, Ruth |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9310634 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Centers for Disease Control and Prevention |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-93106342022-08-03 Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022 Link-Gelles, Ruth Levy, Matthew E. Gaglani, Manjusha Irving, Stephanie A. Stockwell, Melissa Dascomb, Kristin DeSilva, Malini B. Reese, Sarah E. Liao, I-Chia Ong, Toan C. Grannis, Shaun J. McEvoy, Charlene Patel, Palak Klein, Nicola P. Hartmann, Emily Stenehjem, Edward Natarajan, Karthik Naleway, Allison L. Murthy, Kempapura Rao, Suchitra Dixon, Brian E. Kharbanda, Anupam B. Akinseye, Akintunde Dickerson, Monica Lewis, Ned Grisel, Nancy Han, Jungmi Barron, Michelle A. Fadel, William F. Dunne, Margaret M. Goddard, Kristin Arndorfer, Julie Konatham, Deepika Valvi, Nimish R. Currey, J. C. Fireman, Bruce Raiyani, Chandni Zerbo, Ousseny Sloan-Aagard, Chantel Ball, Sarah W. Thompson, Mark G. Tenforde, Mark W. MMWR Morb Mortal Wkly Rep Full Report Centers for Disease Control and Prevention 2022-07-22 /pmc/articles/PMC9310634/ /pubmed/35862287 http://dx.doi.org/10.15585/mmwr.mm7129e1 Text en https://creativecommons.org/publicdomain/zero/1.0/All material in the MMWR Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated. |
| spellingShingle | Full Report Link-Gelles, Ruth Levy, Matthew E. Gaglani, Manjusha Irving, Stephanie A. Stockwell, Melissa Dascomb, Kristin DeSilva, Malini B. Reese, Sarah E. Liao, I-Chia Ong, Toan C. Grannis, Shaun J. McEvoy, Charlene Patel, Palak Klein, Nicola P. Hartmann, Emily Stenehjem, Edward Natarajan, Karthik Naleway, Allison L. Murthy, Kempapura Rao, Suchitra Dixon, Brian E. Kharbanda, Anupam B. Akinseye, Akintunde Dickerson, Monica Lewis, Ned Grisel, Nancy Han, Jungmi Barron, Michelle A. Fadel, William F. Dunne, Margaret M. Goddard, Kristin Arndorfer, Julie Konatham, Deepika Valvi, Nimish R. Currey, J. C. Fireman, Bruce Raiyani, Chandni Zerbo, Ousseny Sloan-Aagard, Chantel Ball, Sarah W. Thompson, Mark G. Tenforde, Mark W. Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022 |
| title | Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022 |
| title_full | Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022 |
| title_fullStr | Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022 |
| title_full_unstemmed | Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022 |
| title_short | Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated — VISION Network, 10 States, December 2021–June 2022 |
| title_sort | effectiveness of 2, 3, and 4 covid-19 mrna vaccine doses among immunocompetent adults during periods when sars-cov-2 omicron ba.1 and ba.2/ba.2.12.1 sublineages predominated — vision network, 10 states, december 2021–june 2022 |
| topic | Full Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310634/ https://www.ncbi.nlm.nih.gov/pubmed/35862287 http://dx.doi.org/10.15585/mmwr.mm7129e1 |
| work_keys_str_mv | AT linkgellesruth effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT levymatthewe effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT gaglanimanjusha effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT irvingstephaniea effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT stockwellmelissa effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT dascombkristin effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT desilvamalinib effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT reesesarahe effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT liaoichia effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT ongtoanc effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT grannisshaunj effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT mcevoycharlene effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT patelpalak effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT kleinnicolap effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT hartmannemily effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT stenehjemedward effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT natarajankarthik effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT nalewayallisonl effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT murthykempapura effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT raosuchitra effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT dixonbriane effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT kharbandaanupamb effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT akinseyeakintunde effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT dickersonmonica effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT lewisned effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT griselnancy effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT hanjungmi effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT barronmichellea effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT fadelwilliamf effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT dunnemargaretm effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT goddardkristin effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT arndorferjulie effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT konathamdeepika effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT valvinimishr effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT curreyjc effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT firemanbruce effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT raiyanichandni effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT zerboousseny effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT sloanaagardchantel effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT ballsarahw effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT thompsonmarkg effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 AT tenfordemarkw effectivenessof23and4covid19mrnavaccinedosesamongimmunocompetentadultsduringperiodswhensarscov2omicronba1andba2ba2121sublineagespredominatedvisionnetwork10statesdecember2021june2022 |